Executive Interviews

  1. One Small Startup’s Quest For Funding Gets Creative
    1/9/2018

    As CEO of Ensysce Biosciences, a semi-virtual company with three employees, Lynn Kirkpatrick, Ph.D., knows all about the funding struggles of a small company.

  2. Breaking The Mold — A New Perspective On Alzheimer’s
    1/9/2018

    Casey Lynch has long had the gut feeling there was more to the cause of Alzheimer’s than beta amyloid and tau proteins. Turns out, she was right.

  3. Industry Explorers Blaze On: Pat Andrews
    1/9/2018

    A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.

  4. Christi Shaw: Empathy Key To Transforming The Patient Experience
    1/9/2018

    The industry veteran talks about leaving Novartis to take care of her sister for a year and how that prepared her for her new job at Lilly.

  5. Can Joseph Papa Save Valeant?
    1/9/2018

    When Joseph Papa took over Valeant Pharmaceuticals in May 2016, the company was in turmoil. We catch up with Papa and see how he’s coming with what he calls “the turnaround opportunity of a lifetime.”

  6. A Celgene Exec's Unexpected Trip To Washington, D.C.
    1/9/2018

    Recounting what an executive did while on sabbatical wouldn’t normally fit into our editorial model. That is, unless that executive is Richard Bagger, J.D., EVP of corporate affairs and market access for Celgene.

  7. Not a Bad Year, After All
    1/9/2018

    Peter Meath, who heads the Life Science Group at J.P. Morgan’s Commercial Banking business, offers advice to novice entrepreneurs for turning a company’s novel science into a viable business.

  8. 5 Leadership Questions For Camilla Harder Hartvig
    1/9/2018

    Camilla Harder Hartvig is SVP of Canada and EMEA for Alexion Pharmaceuticals. Previously she was president, Europe and emerging markets, at Glenmark Pharmaceuticals and also worked for companies such as Allergan, AstraZeneca, and Novartis in various managerial positions.

  9. 2018: The Year Of Biosimilar Commercialization Wins Or Woes?
    12/7/2017

    We reached out to eight experts from biosimilar companies and consulting firms to see which topics they’ve been watching closely throughout 2017 and how they expect these trends will evolve and challenge the industry in 2018.

  10. The Women Of Biopharma — Will They Gain Or Lose Ground In 2018?
    12/7/2017

    We hear from 11 women and one man in biopharma. Although we were not aiming for “balance” here — there are plenty of opposing opinions out there already — the sole gender-exception in this group supplies another valuable viewpoint…